Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 3, 2014, Pages 651-663

  Munday, Jane C ^a,b   Eze, Anthonius A ^a,c   Baker, Nicola ^d,g   Glover, Lucy ^d,g   Clucas, Caroline ^a,b   Andrés, David Aguinaga ^a   Natto, Manal J ^a   Teka, Ibrahim A ^a   Mcdonald, Jennifer ^a   Lee, Rebecca S ^a   Graf, Fabrice E ^e,f   Ludin, Philipp ^e,f   Burchmore, Richard J S ^a   Turner, C Michael R ^a   Tait, Andy ^a   Macleod, Annette ^a,b   Mäser, Pascal ^e,f   Barrett, Michael P ^a,b   Horn, David ^d,g   De Koning, Harry P ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF NIGERIA   (Nigeria)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^f UNIVERSITY OF BASEL   (Switzerland)

^g UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Aquaporin; Drug transport; Parasite; Protozoan; Resistance mutation

Indexed keywords

ANTITRYPANOSOMAL AGENT; AQUAGLYCEROPORIN; MELARSOPROL; PENTAMIDINE;

ALLELE; DNA SEQUENCE; DRUG EFFECTS; DRUG RESISTANCE; GENE; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL; TRYPANOSOMA BRUCEI BRUCEI;

ALLELES; AQUAGLYCEROPORINS; BIOLOGICAL TRANSPORT; DRUG RESISTANCE; GENES, PROTOZOAN; MELARSOPROL; PENTAMIDINE; SEQUENCE ANALYSIS, DNA; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI;

EID: 84894096486     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt442     Document Type: Article

References (58)

1. Franco JR, Simarro PP, Diarra A et al. Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis. Res Rep Trop Med 2012; 3: 93-101.
2. Delespaux V, De Koning HP. Drugs and drug resistance in African trypanosomiasis. Drug Resist Update 2007; 10: 30-50.
3. Brun R, Schumacher R, Schmid C et al. The phenomenon of treatment failures in human African trypanosomiasis. Trop Med Int Health 2001; 6: 906-14.
4. Rollo IM, Williamson J. Acquired resistance to 'melarsen', tryparsamide and amidines in pathogenic trypanosomes after treatment with 'melarsen' alone. Nature 1951; 167: 147-8.
5. Damper D, Patton CL. Pentamidine transport and sensitivity in brucei-group trypanosomes. J Protozool 1976; 23: 349-56.
6. Frommel TO, Balber AE. Flow cytofluorimetric analysis of drug accumulation by multidrug-resistant Trypanosoma brucei brucei and T. b. rhodesiense. Mol Biochem Parasitol 1987; 26: 183-91.
7. De Koning HP. Transporters in African trypanosomes: role in drug action and resistance. Int J Parasitol 2001; 31: 512-22.
8. Carter NS, Fairlamb AH. Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 1993; 361: 173-6.
9. Carter NS, Berger BJ, Fairlamb AH. Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J Biol Chem 1995; 270: 28153-7.
10. Barrett MP, Zhang ZQ, Denise H et al. A diamidine-resistant Trypanosoma equiperdum clone contains a P2 purine transporter with reduced substrate affinity. Mol Biochem Parasitol 1995; 73: 223-9.
11. Carter NS, BarrettMP,De KoningHP.Adrug resistance determinant from Trypanosoma brucei. Trends Microbiol 1999; 7: 469-71.
12. Mä ser P, Sutterlin C, Kralli A et al. A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 1999; 285: 242-4.
13. De Koning HP, Bridges DJ, Burchmore R. Purine transporters of protozoa: from biology to therapy. FEMS Microbiol Rev 2005; 29: 987-1020.
14. Matovu E, Stewart M, Geiser F et al. The mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot Cell 2003; 2: 1003-8.
15. Ward CP, Wong PE, Burchmore RJ et al. Trypanocidal furamidine analogues: influence of pyridine nitrogens on trypanocidal activity, transport kinetics and resistance patterns. Antimicrob Agents Chemother 2011; 55: 2352-61.
16. Bridges D, Gould MK, Nerima B et al. Loss of the high affinity pentamidine transporter is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes. Mol Pharmacol 2007; 71: 1098-108.
17. De Koning HP. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters. Implications for cross resistance with arsenicals. Mol Pharmacol 2001; 59: 586-92.
18. De Koning HP, Jarvis SM. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by the P2 adenosine transporter and at least one novel, unrelated transporter. Acta Trop 2001; 80: 245-50.
19. Bray PG, Barrett MP,Ward SA et al. Pentamidine uptake and resistance in pathogenic protozoa. Trends Parasitol 2003; 19: 232-9.
20. Baker N, Glover L, Aguinaga A et al. Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. Proc Natl Acad Sci USA 2012; 109: 10996-1001.
21. Benga G, Waterchannel proteins (later called aquaporins) and relatives: past, present, and future. IUBMB Life 2009; 61: 112-33.
22. Verkman AS. Aquaporins in clinical medicine. Annu Rev Med 2012; 63, 303-16.
23. Huber VJ, Tsujita M, Nakada T. Aquaporins in drug discovery and pharmacotherapy. Mol Aspects Med 2012; 33: 691-703.
24. Wu B, Beitz E. Aquaporins with selectivity for unconventional permeants. Cell Mol Life Sci 2007; 64: 2413-21.
25. Liu Z, Shen J, Carbrey JM et al. Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc Natl Acad Sci USA 2002; 99: 6053-8.
26. Mukhopadhyay R, Mandal G, Atluri VS et al. The role of alanine 163 in solute permeability of Leishmania major aquaglyceroporin LmAQP1. Mol Biochem Parasitol 2011; 175: 83-90.
27. Uzcategui NL, Szallies A, Pavlovic-Djuranovic S et al. Cloning, heterologous expression, and characterization of three aquaglyceroporins from Trypanosoma brucei. J Biol Chem 2004; 279: 42669-76.
28. Bassarak B, Uzcátegui NL, Schönfeld C et al. Functional characterization of three aquaglyceroporins from Trypanosoma brucei in osmoregulation and glycerol transport. Cell Physiol Biochem 2011; 27: 411-20.
29. Baker N, De Koning HP, Mäser P et al. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol 2013; 29: 110-8.
30. Tsukaguchi H,Weremowicz S, Morton CC et al. Functional and molecular characterization of the human neutral solute channel aquaporin-9. Am J Physiol 1999; 277: F685-96.
31. Alsford S, Horn D. Single-locus targeting constructs for reliable regulated RNAi and transgene expression in Trypanosoma brucei. Mol Biochem Parasitol 2008; 161: 76-9.
32. Alsford S, Eckert S, Baker N et al. High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 2012; 482: 232-6.
33. Scott AG, Tait A, Turner CMR. Characterisation of cloned lines of Trypanosoma brucei expressing stable resistance to MelCy and Suramin. Acta Trop 1996; 60: 251-62.
34. Peacock L, Ferris VR, Bailey M et al. Fly transmission and mating of Trypanosoma brucei brucei strain 427. Mol Biochem Parasitol 2008; 160: 100-6.
35. Al-Salabi MI, De Koning HP. Purine nucleobase transport in amastigotes of Leishmania mexicana: involvement in allopurinol uptake. Antimicrob Agents Chemother 2005; 49: 3682-9.
36. Al-Salabi MI, Wallace LJM, De Koning HP. A Leishmania major nucleobase transporter responsible for allopurinol uptake is a functional homologue of the Trypanosoma brucei H2 transporter. Mol Pharmacol 2003; 63: 814-20.
37. Biebinger S, Wirtz LE, Lorenz P et al. Vectors for inducible expression of toxic gene products in bloodstream and procyclic Trypanosoma brucei. Mol Biochem Parasitol 1997; 85: 99-112.
38. Alsford S, Kawahara T, Glover L et al. Tagging a T. brucei RRNA locus improves stable transfection efficiency and circumvents inducible expression position effects. Mol Biochem Parasitol 2005; 144: 142-8.
39. Burkard G, Fragoso CM, Roditi I. Highly efficient stable transformation of bloodstream forms of Trypanosoma brucei. Mol Biochem Parasitol 2007; 153: 220-3.
40. Berriman M, Ghedin E, Hertz-Fowler C et al. The genome of the African trypanosome Trypanosoma brucei. Science 2005; 309: 416-22.
41. Li H,Handsaker B,Wysoker A et al. The SequenceAlignment/Mapformat and SAMtools. Bioinformatics 2009; 25: 2078-9.
42. Carver T, Harris SR, Berriman M et al. Artemis: an integrated platform for visualization and analysis of high-throughput sequence-based experimental data. Bioinformatics 2012; 28: 464-9.
43. Al-Salabi MI, Wallace LJM, Lüscher A et al. Molecular interactions underlying the unusually high affinity of a novel Trypanosoma brucei nucleoside transporter. Mol Pharmacol 2007; 71: 921-9.
44. Natto M,Wallace LJM, Candlish D et al. Trypanosoma brucei: expression of multiple purine transporters prevents the development of allopurinol resistance. Exp Parasitol 2005; 109: 80-6.
45. Wallace LJM, Candlish D, De Koning HP. Different substrate recognition motifs of human and trypanosome nucleobase transporters: selective uptake of purine antimetabolites. J Biol Chem 2002; 277: 26149-56.
46. Papageorgiou IG, Yakob L, Al Salabi MI et al. Identification of the first pyrimidine nucleobase transporter in Leishmania: similarities with the Trypanosoma brucei U1 transporter and antileishmanial activity of uracil analogues. Parasitology 2005; 130: 275-83.
47. Gould MK, Vu XL, Seebeck T et al. Propidium iodide-based methods for monitoring drug action in the kinetoplastidae: comparison with the Alamar blue assay. Anal Biochem 2008; 382: 87-93.
48. IbrahimHM,Al-Salabi MI, ElSabbagh N et al. Symmetricalcholine-derived dications display strong anti-kinetoplastid activity. J Antimicrob Chemother 2011; 66: 111-25.
49. Tetaud E, Lecuix I, Sheldrake T et al. A new expression vector for Crithidia fasciculata and Leishmania. Mol Biochem Parasitol 2002; 120: 195-204.
50. De Koning HP, Stewart M, Anderson L et al. The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter; additional insights in diamidine resistance in African trypanosomes. Antimicrob Agents Chemother 2004; 48: 1515-9.
51. De Koning HP. The ever-increasing complexities of arsenical-diamidine cross-resistance in African trypanosomes. Trends Parasitol 2008; 24: 345-9.
52. Scott AG, Tait A, Turner CMR. Trypanosoma brucei: lack of crossresistance to melarsoprol in vitro by cymelarsan-resistant parasites. Exp Parasitol 1997; 86: 181-90.
53. De Koning HP, Jarvis SM. Adenosine transporters in bloodstream forms of T. b. brucei: substrate recognition motifs and affinity for trypanocidal drugs. Mol Pharmacol 1999; 56: 1162-70.
54. Chattopadhyay A, Jafurulla M. A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis. Biochem Biophys Res Commun 2011; 416: 7-12.
55. Geiser F, Lüscher A, De Koning HP et al. Molecular pharmacology of adenosine transport in Trypanosoma brucei: P1/P2 revisited. Mol Pharmacol 2005; 68: 589-95.
56. Bernhard SC, Nerima B, Mäser P et al. Melarsoprol- and pentamidineresistant Trypanosoma brucei rhodesiense populations and their crossresistance. Int J Parasitol 2007; 37: 1443-8.
57. Stewart ML, Burchmore RJS, Clucas Cet al. Multiple genetic mechanisms lead to the loss of functional TbAT1 expression in drug resistant trypanosomes. Eukaryot Cell 2010; 9: 336-43.
58. Munday JC, Rojas López KE, Eze AA et al. Functional expression of TcoAT1 reveals it to be a P1-type nucleoside transporter with no capacity for diminazene uptake. Int J Parasitol Drugs Drug Resist 2013; 3: 69-76.